SOPHiA GENETICS (SOPH)
(Delayed Data from NSDQ)
$3.69 USD
-0.06 (-1.60%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $3.63 -0.06 (-1.63%) 7:04 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
SOPH 3.69 -0.06(-1.60%)
Will SOPH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SOPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SOPH
SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes SOPHiA GENETICS (SOPH) a New Buy Stock
SOPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates
Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
Other News for SOPH
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024
SOPHiA GENETICS Unveils New Generation of the SOPHiA DDMTM Platform at Morgan Stanley Healthcare Conference 2024
SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference
Tracking Al Gore's Generation Investment Management Portfolio - Q2 2024 Update
Sophia Genetics announces CE mark for Sophia DDM Platform under IVDR